What pharmacologic options are available to treat cravings in alcohol use disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Pharmacologic Options for Alcohol Craving

For patients with alcohol use disorder seeking to reduce cravings and prevent relapse, acamprosate (666 mg three times daily) is the first-line medication with the strongest evidence for maintaining abstinence, while naltrexone (50 mg daily oral or 380 mg monthly injectable) serves as first-line for reducing heavy drinking, with baclofen (30-60 mg daily) as a viable alternative particularly in patients with liver disease. 1

FDA-Approved Medications

The three FDA-approved medications for alcohol use disorder work through distinct mechanisms:

Acamprosate (First-Line for Abstinence Maintenance)

  • Dosing: 666 mg (two 333 mg tablets) three times daily 1
  • Mechanism: NMDA receptor antagonist that reduces withdrawal effects and craving 1
  • Key advantage: No hepatic metabolism, making it the safest option in liver disease with no reported hepatotoxicity 1
  • Number needed to treat: Approximately 12 to prevent return to any drinking 1
  • Timing: Start 3-7 days after last drink, once withdrawal symptoms resolve 2
  • Duration: 3-6 months typical treatment period 2
  • Evidence quality: Strongest evidence from network meta-analysis showing superiority over placebo for maintaining abstinence 3

Naltrexone (First-Line for Reducing Heavy Drinking)

  • Dosing: 50 mg daily oral (start 25 mg for 1-3 days) OR 380 mg monthly intramuscular 1, 2
  • Mechanism: Opioid receptor antagonist that dampens alcohol reward pathway 1, 2
  • Number needed to treat: Approximately 20 1
  • Critical caveat: Undergoes hepatic metabolism with hepatotoxicity concerns—not recommended in patients with active liver disease 1, 4
  • Duration: 3-12 months 2
  • Breakthrough craving: For patients on extended-release injectable experiencing late-cycle breakthrough craving, adjunctive as-needed oral naltrexone (50 mg) can be added 5

Disulfiram

  • Not recommended as first-line due to hepatotoxicity risk in liver disease and requirement for high patient motivation 1, 4, 2
  • Explicitly contraindicated in patients with severe alcoholic liver disease 1, 4

Non-FDA Approved Options with Evidence

Baclofen (Second-Line, Especially with Liver Disease)

  • Dosing: 30-60 mg daily (typically 10 mg three times daily) 1, 2, 1
  • Mechanism: GABA-B receptor agonist 1
  • Unique advantage: Only medication tested in RCT specifically in patients with cirrhosis, showing improved abstinence rates over 12 weeks 1, 2, 1
  • Important warning: Exclude patients with hepatic encephalopathy as baclofen may worsen mental status 1
  • Monitoring: Watch for renal dysfunction and sedation 1

Gabapentin

  • Dosing: 600-1,800 mg daily 1
  • Mechanism: Modulates GABA activity 1
  • Advantage: No hepatic metabolism (renal excretion) 1
  • Monitoring: Renal function and mental status/sedation 1

Topiramate

  • Dosing: 75-400 mg daily (start 25 mg, titrate to 100 mg) 1, 2
  • Mechanism: GABA augmentation and glutamate antagonism 1
  • Evidence: Shows promise in reducing heavy drinking 4
  • Advantage: Not extensively metabolized, primarily renal excretion 1

Clinical Decision Algorithm

For patients WITHOUT liver disease:

  1. Goal = Reduce drinking: Start naltrexone 50 mg daily (or 380 mg IM monthly)
  2. Goal = Maintain abstinence: Start acamprosate 666 mg three times daily
  3. Partial response: Add second agent or switch to topiramate/gabapentin
  4. Breakthrough craving on injectable naltrexone: Add oral naltrexone 50 mg as needed 5

For patients WITH liver disease (compensated or decompensated cirrhosis):

  1. First choice: Acamprosate 666 mg three times daily (safest hepatic profile) 1
  2. Second choice: Baclofen 30-60 mg daily (only medication with RCT data in cirrhosis) 1, 2, 1
  3. Avoid: Naltrexone and disulfiram (hepatotoxicity risk) 1, 4
  4. Consider: Gabapentin if renal function adequate 1

For patients WITH renal impairment:

  • Avoid: Acamprosate, gabapentin (renal excretion) 1
  • Consider: Baclofen with dose adjustment, though monitor closely 1

Critical Pitfalls to Avoid

  • Do not use naltrexone in active liver disease—despite being FDA-approved, it carries hepatotoxicity risk and lacks safety data in this population 1, 4
  • Do not use disulfiram in severe alcoholic liver disease—explicit contraindication due to hepatotoxicity 1, 4, 2
  • Do not use baclofen in patients with hepatic encephalopathy—may worsen mental status 1
  • Do not start acamprosate during active withdrawal—wait 3-7 days after last drink until withdrawal resolves 2
  • Do not rely on medication alone—combine with cognitive behavioral therapy, motivational enhancement therapy, or other evidence-based psychosocial treatment for optimal outcomes 1, 6

Combination Therapy

While individual medications show modest effect sizes (NNT 12-20), combining pharmacotherapy with structured psychosocial treatment (CBT, motivational enhancement therapy) significantly improves outcomes compared to usual care alone 1, 6. The evidence supports integrating addiction treatment with medical care rather than simple referral 1.

Consider combining medications (e.g., naltrexone plus acamprosate) in highly adherent patients with severe disease, though this remains an emerging area with limited direct evidence 7.

References

Related Questions

What are the recommended pharmacologic and psychosocial treatment options for alcohol use disorder, including considerations for hepatic impairment and renal function?
What is the best multivitamin for an adult patient who chronically abuses alcohol?
What pharmacologic treatments are recommended for an adult with alcohol use disorder who has no contraindicating medical conditions, including considerations of hepatic function?
In a 48-year-old man who wants to reduce his alcohol consumption but cannot do so on his own, which is the appropriate recommendation: naltrexone, acamprosate, disulfiram, or referral to a 12‑step program?
What is the safest first-line anxiolytic medication for an adult with alcohol use disorder?
What is the differential diagnosis for gynecomastia in a male patient?
Can I start sulfasalazine in a child with juvenile idiopathic arthritis who is on antituberculous therapy, assuming no sulfa allergy, no glucose‑6‑phosphate dehydrogenase deficiency, and acceptable liver function?
In a 75-year-old woman with Waldenström macroglobulinemia presenting with hyperviscosity syndrome (headache, intermittent confusion, fever) and an IgM monoclonal spike with serum protein of 6.9 g/dL, what is the recommended first-line therapy?
In a patient restarting clozapine at 25 mg nightly after normal laboratory results, how should the dose be increased and what is the appropriate timing for titration?
What is the recommended treatment plan for a patient with mixed‑type attention‑deficit/hyperactivity disorder (ADHD) who also has moderate depression and mild anxiety?
What is an appropriate taper schedule for liquid clonazepam (Klonopin) at a dose of 0.375 mg in the morning and 0.125 mg in the evening?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.